Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status

Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer>10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p<0.0001) was found across all samples, but no association between size and SN status (p=0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p=0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p=0.01). Overall survival was significantly lower (p=0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status.

Automated summary

In this study, researchers found that molecular subtypes derived from primary breast cancers provided additional predictive value for sentinel lymph node biopsy (SLNB) status. BasL subtype and hormone receptor activity were important factors in predicting SLNB status.